The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: Results from a multicenter randomized controlled trial
Takeshi Tominaga(Tokyo Metropolitan Komagome Hospital), Susumu Yamaguchi(Hokkaido University Hospital), Minoru Yoshida(RIKEN Center for Sustainable Resource Science), Kazuaki Asaishi(Hokkaido University Hospital), T Senoo(SHOWA Medical University), Osahiko Abe(Keio University), Hiroshi Sonoo(Okayama Prefecture), M Izuo(SHOWA Medical University), Takao Hattori(Hiroshima University), Izo Kimijima(Hokkaido University Hospital), Yasuo Ohashi(Chuo University), Masakazu Toi(Mukogawa Women's University), Koichi Hirata(Japan Coal Energy Center), Shigeto Miura(Tohoku University), Hiroki Koyama(Osaka Medical Center for Cancer and Cardiovascular Diseases), Junichi Uchino(SHOWA Medical University), Yasumasa Monden(Hokkaido University Hospital), Kohji Enomoto(SHOWA Medical University), Rikiya Abe(Second Hospital of Nanchang), Jun Ota(Hokkaido University Hospital), Tadaoki Morimoto(Hokkaido University Hospital), Hiroaki Nakazato, Yasuo Nomura(Hokkaido University Hospital), T Taguchi(Japan Society of Chemotherapy), Keizō Sugimachi(Kyushu University), Hiromu Watanabe(SHOWA Medical University), Tetsuya Toge(Hiroshima University), Hiroshi Hayasaka(SHOWA Medical University)
Cited by 10
Related Papers
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
|Cold Spring Harbor Perspectives in Biology|2014|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k